Published in J Am Chem Soc on August 30, 2008
Three decades of beta-lactamase inhibitors. Clin Microbiol Rev (2010) 5.54
Carbapenems: past, present, and future. Antimicrob Agents Chemother (2011) 2.61
Metallo-β-lactamase structure and function. Ann N Y Acad Sci (2012) 1.36
Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem. Biochemistry (2010) 1.23
Structures of the class D carbapenemase OXA-24 from Acinetobacter baumannii in complex with doripenem. J Mol Biol (2011) 1.22
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. Antimicrob Agents Chemother (2010) 1.17
The 1.4 A crystal structure of the class D beta-lactamase OXA-1 complexed with doripenem. Biochemistry (2009) 1.16
Design, synthesis, and crystal structures of 6-alkylidene-2'-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase. J Am Chem Soc (2010) 1.12
The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276. Biochemistry (2009) 1.06
Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design. Biochemistry (2010) 1.06
Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2. Biochemistry (2010) 1.01
Structures of the Michaelis complex (1.2 Å) and the covalent acyl intermediate (2.0 Å) of cefamandole bound in the active sites of the Mycobacterium tuberculosis β-lactamase K73A and E166A mutants. Biochemistry (2010) 0.97
Carbapenems and SHV-1 beta-lactamase form different acyl-enzyme populations in crystals and solution. Biochemistry (2008) 0.95
Class D β-lactamases: a reappraisal after five decades. Acc Chem Res (2013) 0.92
Insights into β-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants. J Biol Chem (2013) 0.89
Reappraising the use of β-lactams to treat tuberculosis. Expert Rev Anti Infect Ther (2012) 0.88
Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems. Antimicrob Agents Chemother (2011) 0.87
Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance. Int J Mol Sci (2015) 0.86
Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations. Antimicrob Agents Chemother (2013) 0.84
Structural analysis of the role of Pseudomonas aeruginosa penicillin-binding protein 5 in β-lactam resistance. Antimicrob Agents Chemother (2013) 0.83
Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance. Antimicrob Agents Chemother (2012) 0.82
Structural basis for progression toward the carbapenemase activity in the GES family of β-lactamases. J Am Chem Soc (2012) 0.82
Natural Variants of the KPC-2 Carbapenemase have Evolved Increased Catalytic Efficiency for Ceftazidime Hydrolysis at the Cost of Enzyme Stability. PLoS Pathog (2015) 0.80
Crystallographic snapshots of Class A β-lactamase catalysis reveal structural changes that facilitate β-lactam hydrolysis. J Biol Chem (2017) 0.75
Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients. ACS Infect Dis (2017) 0.75
Predicting allosteric mutants that increase activity of a major antibiotic resistance enzyme. Chem Sci (2017) 0.75
SHELXL: high-resolution refinement. Methods Enzymol (1997) 43.04
Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature (1992) 36.50
XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. J Struct Biol (1999) 17.84
Raster3D Version 2.0. A program for photorealistic molecular graphics. Acta Crystallogr D Biol Crystallogr (1994) 17.44
Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev (2005) 12.07
Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect (2002) 8.93
Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev (2005) 4.48
Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother (2005) 4.17
The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol (2006) 3.96
Carbapenemases: molecular diversity and clinical consequences. Future Microbiol (2007) 3.67
GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother (2001) 3.39
OXA-type carbapenemases. J Antimicrob Chemother (2006) 3.15
The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs (2002) 2.41
Mutagenesis of amino acid residues in the SHV-1 beta-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance. Biochim Biophys Acta (2001) 1.92
Structure of the SHV-1 beta-lactamase. Biochemistry (1999) 1.87
An ultrahigh resolution structure of TEM-1 beta-lactamase suggests a role for Glu166 as the general base in acylation. J Am Chem Soc (2002) 1.81
Carbapenems as inhibitors of OXA-13, a novel, integron-encoded beta-lactamase in Pseudomonas aeruginosa. Microbiology (1998) 1.72
Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C beta-lactamase. Mol Microbiol (2006) 1.70
Expanding the model: anisotropic displacement parameters in protein structure refinement. Acta Crystallogr D Biol Crystallogr (1999) 1.69
Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J Mol Biol (2003) 1.66
Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance. J Biol Chem (2006) 1.60
How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention. Adv Exp Med Biol (1998) 1.58
Crystal structures of the class D beta-lactamase OXA-13 in the native form and in complex with meropenem. J Mol Biol (2001) 1.54
Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV beta-lactamase that compromises the efficacy of imipenem. Antimicrob Agents Chemother (2003) 1.53
Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam. Biochemistry (2001) 1.49
Beta-lactamases: a survey of protein diversity. Curr Drug Targets Infect Disord (2003) 1.41
Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130. J Biol Chem (2003) 1.41
Structural basis for imipenem inhibition of class C beta-lactamases. Antimicrob Agents Chemother (2002) 1.39
Carbapenemases. J Antimicrob Chemother (1992) 1.29
Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams. Proteins (2002) 1.27
Role of Asp104 in the SHV beta-lactamase. Antimicrob Agents Chemother (2006) 1.21
Imipenem as substrate and inhibitor of beta-lactamases. Biochem J (1988) 1.12
Clinical strategies for serious infection: a North American perspective. Diagn Microbiol Infect Dis (1998) 1.01
Serious infections caused by enteric gram-negative bacilli--mechanisms of antibiotic resistance and implications for therapy of gram-negative sepsis in the transplanted patient. Semin Respir Infect (2002) 0.88
SME-2-producing Serratia marcescens isolate from Switzerland. Antimicrob Agents Chemother (2007) 0.82
What's new in the antibiotic pipeline. Curr Opin Microbiol (1999) 0.81
Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev (2005) 15.72
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis (2013) 6.60
Three decades of beta-lactamase inhibitors. Clin Microbiol Rev (2010) 5.54
Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother (2006) 4.80
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med (2004) 4.75
Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J Bacteriol (2008) 4.42
Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 4.27
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis (2013) 4.07
Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases. Antimicrob Agents Chemother (2003) 3.92
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother (2009) 3.82
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis (2004) 3.75
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother (2009) 2.96
"Stormy waters ahead": global emergence of carbapenemases. Front Microbiol (2013) 2.74
Carbapenems: past, present, and future. Antimicrob Agents Chemother (2011) 2.61
Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae. Proc Natl Acad Sci U S A (2014) 2.56
Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother (2009) 2.28
Multiplex real-time PCR assay for detection and classification of Klebsiella pneumoniae carbapenemase gene (bla KPC) variants. J Clin Microbiol (2010) 2.18
Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother (2011) 2.18
Occurrence, distribution, and origins of Streptococcus pneumoniae Serotype 6C, a recently recognized serotype. J Clin Microbiol (2008) 2.17
Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio (2012) 2.15
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother (2009) 2.12
The continuing challenge of ESBLs. Curr Opin Pharmacol (2007) 2.12
Isolation and characterization of an autoinducer synthase from Acinetobacter baumannii. J Bacteriol (2008) 2.02
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis (2013) 2.01
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. Antimicrob Agents Chemother (2009) 1.96
Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother (2010) 1.94
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2010) 1.94
Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis. J Biol Chem (2012) 1.93
Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry (2003) 1.89
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother (2008) 1.89
Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother (2005) 1.88
Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother (2010) 1.87
In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother (2009) 1.80
Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. J Clin Microbiol (2004) 1.80
The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril! Curr Opin Microbiol (2005) 1.77
Development of a sensitive and specific enzyme-linked immunosorbent assay for detecting and quantifying CMY-2 and SHV beta-lactamases. J Clin Microbiol (2002) 1.75
3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J Biol Chem (2005) 1.75
Crystal structure of KPC-2: insights into carbapenemase activity in class A beta-lactamases. Biochemistry (2007) 1.74
Complete nucleotide sequences of blaKPC-4- and blaKPC-5-harboring IncN and IncX plasmids from Klebsiella pneumoniae strains isolated in New Jersey. Antimicrob Agents Chemother (2012) 1.70
Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center. Infect Control Hosp Epidemiol (2011) 1.70
Comparison of beta-lactamases of classes A and D: 1.5-A crystallographic structure of the class D OXA-1 oxacillinase. Protein Sci (2003) 1.67
Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J Mol Biol (2003) 1.66
Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis (2011) 1.64
Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance. J Biol Chem (2006) 1.60
Complete nucleotide sequence of a blaKPC-harboring IncI2 plasmid and its dissemination in New Jersey and New York hospitals. Antimicrob Agents Chemother (2013) 1.59
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2010) 1.58
Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type beta-lactamase genes in Gram-negative isolates. J Clin Microbiol (2010) 1.55
Genomewide analysis of divergence of antibiotic resistance determinants in closely related isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2010) 1.55
Use of denaturing gradient gel electrophoresis for analysis of the stool microbiota of hospitalized patients. J Microbiol Methods (2003) 1.54
First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the "menace" arrives in the new world. J Clin Microbiol (2012) 1.52
Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob Agents Chemother (2004) 1.52
New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. MBio (2014) 1.51
The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrob Agents Chemother (2008) 1.47
New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother (2013) 1.47
Multiplex real-time PCR for detection of an epidemic KPC-producing Klebsiella pneumoniae ST258 clone. Antimicrob Agents Chemother (2012) 1.46
"Salvage microbiology": detection of bacteria directly from clinical specimens following initiation of antimicrobial treatment. PLoS One (2013) 1.45
Genetic analysis of surface motility in Acinetobacter baumannii. Microbiology (2011) 1.44
Malaria parasite invasion of the mosquito salivary gland requires interaction between the Plasmodium TRAP and the Anopheles saglin proteins. PLoS Pathog (2009) 1.44
Extended-spectrum beta-lactamases in multidrug-resistant Escherichia coli: changing the therapy for hospital-acquired and community-acquired infections. Clin Infect Dis (2006) 1.43
New Delhi metallo-β-lactamase and multidrug resistance: a global SOS? Clin Infect Dis (2011) 1.41
Beta-lactamases: a survey of protein diversity. Curr Drug Targets Infect Disord (2003) 1.41
Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130. J Biol Chem (2003) 1.41
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. Antimicrob Agents Chemother (2010) 1.41
What's new in antibiotic resistance? Focus on beta-lactamases. Drug Resist Updat (2006) 1.41
Status report on carbapenemases: challenges and prospects. Expert Rev Anti Infect Ther (2011) 1.40